Chapter 8  ·  Module 3

Class II Agents: Beta-Blockers in Arrhythmia Management

Four antiarrhythmic mechanisms, key agents, and high-yield clinical applications

Four Antiarrhythmic Mechanisms of Beta-Blockers

Phase 4 Automaticity Reduction

Blocks catecholamine-driven steepening of the phase 4 pacemaker slope in sinoatrial and Purkinje cells

Slows sinoatrial node; suppresses subsidiary pacemakers

Sinus tachycardia, exercise-induced arrhythmias

Atrioventricular Nodal Slowing

Reduces calcium current in nodal cells, prolonging atrioventricular nodal refractoriness

PR interval prolongation on electrocardiogram

Atrial fibrillation rate control, supraventricular tachycardia

Triggered Activity Suppression

Reduces catecholamine-driven calcium overload, preventing delayed afterdepolarizations

Catecholaminergic polymorphic ventricular tachycardia, Long QT Syndrome, thyroid storm

Ischemic Substrate Reduction

Reduces myocardial oxygen demand; reduces repolarization heterogeneity in ischemic tissue

Post-myocardial infarction mortality reduction

Key Beta-Blocker Agents — Properties and Primary Uses

Agent Selectivity Lipophilicity Route Primary Arrhythmia Use
Metoprolol Beta-1 selective Moderate Oral + intravenous Atrial fibrillation rate control; heart failure with reduced ejection fraction (succinate form)
Esmolol Beta-1 selective Moderate Intravenous only Perioperative and intensive care unit tachyarrhythmias; thyroid storm (if propranolol contraindicated); half-life 9 minutes
Propranolol Non-selective (beta-1 + beta-2) High Oral + intravenous Thyroid storm (inhibits T4→T3 conversion); high central nervous system penetration
Nadolol Non-selective (beta-1 + beta-2) Low (hydrophilic) Oral Catecholaminergic polymorphic ventricular tachycardia; Long QT Syndrome Types 1 and 2 — long half-life, consistent levels
Carvedilol Non-selective + alpha-1 block Moderate-high Oral Heart failure with reduced ejection fraction (proven mortality benefit); post-myocardial infarction with left ventricular dysfunction

Indications by Arrhythmia Type

Rate Control

Atrial Fibrillation / Flutter

  • First-line for rate control, especially with heart failure with reduced ejection fraction
  • Superior to digoxin during exercise (sympathetic state)
  • Preferred agent: intravenous metoprolol or esmolol for acute control

Supraventricular Tachycardia

Atrioventricular Node-Dependent Tachycardias

  • Acute termination: adenosine first-line; beta-blockers second
  • Chronic prophylaxis: oral metoprolol or atenolol first-line
  • Blocks atrioventricular nodal limb of re-entrant circuit

Post-MI / Heart Failure

Ventricular Arrhythmia Prevention

  • 30–50% reduction in sudden cardiac death post-myocardial infarction
  • Preferred: carvedilol or metoprolol succinate with left ventricular dysfunction
  • Start only when compensated — never in acute decompensation

Catecholaminergic Polymorphic VT

Exercise-Triggered Ventricular Tachycardia

  • Cornerstone of therapy — nadolol preferred
  • Suppresses delayed afterdepolarizations from calcium overload
  • Never abruptly discontinue — withdrawal precipitates ventricular fibrillation

Long QT Syndrome

Congenital Channelopathies

  • Type 1: highly effective (swim/exertion triggers); nadolol or atenolol
  • Type 2: moderately effective (auditory/arousal triggers)
  • Type 3: limited efficacy; add mexiletine

Thyroid Storm

Catecholamine Hypersensitivity

  • Propranolol preferred: beta-blockade plus inhibition of T4→T3 peripheral conversion
  • Dual action addresses both arrhythmia and hormonal burden
  • Esmolol if propranolol contraindicated (asthma)

Adverse Effects and the Withdrawal Rule

Property-Linked Adverse Effects

Choose Agent to Minimize Risk

  • Bronchospasm: beta-2 blockade — use beta-1 selective agents in reactive airway disease
  • Central nervous system: lipophilicity — use hydrophilic agents (nadolol, atenolol) if fatigue/depression problematic
  • Hypoglycemia masking: use beta-1 selective agents in insulin-dependent diabetics
  • Peripheral vasoconstriction: non-selective — use carvedilol or selective agent in Raynaud's
  • Bradycardia/atrioventricular block: all agents — contraindicated in high-degree block without pacemaker

Absolute Contraindications

Do Not Use In These Settings

  • Decompensated heart failure / acute pulmonary edema
  • Cardiogenic shock
  • Second- or third-degree atrioventricular block without pacemaker
  • Sick sinus syndrome without pacemaker
  • Severe asthma with active bronchospasm (non-selective agents)
  • Cocaine-induced tachycardia (unopposed alpha stimulation)

Withdrawal Warning

Chronic beta-blockade upregulates beta-adrenergic receptor density. Abrupt discontinuation exposes this supersensitive receptor population to endogenous catecholamines, causing rebound tachycardia, angina, and ventricular fibrillation in patients with coronary artery disease, catecholaminergic polymorphic ventricular tachycardia, or Long QT Syndrome. Never abruptly stop. Always taper over 1 to 2 weeks. Continue perioperatively. Bridge with intravenous esmolol if oral therapy must be interrupted.